13F Pro13F Pro

PERCEPTIVE ADVISORS LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1224962
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.9%$6.4B
  • Financials0.1%$8.0M

AUM History

13fpro.ai/research/fund/perceptive-advisors-llc-1224962

Conviction and streaks

Diversifying · top 10 = 48.9%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

PRAX$PRAXConviction hold10.6% weight · held 10 quartersSYRE$SYREConviction hold6.0% weight · held 10 quartersCELC$CELCConviction hold5.2% weight · held 10 quartersRYTM$RYTMConviction hold4.5% weight · held 10 quartersROIV$ROIVConviction hold4.4% weight · held 5 quartersNRIX$NRIXAccumulating+1352% shares · 5 quarters runningZYME$ZYMEAccumulating+228% shares · 4 quarters runningSYRE$SYREAccumulating+251% shares · 3 quarters runningRLAY$RLAYAccumulating+641% shares · 2 quarters runningTNGX$TNGXAccumulating+558% shares · 2 quarters runningADMA$ADMATrimming-92% shares · 5 quarters runningNTRA$NTRATrimming-97% shares · 3 quarters runningTVTX$TVTXTrimming-12% shares · 2 quarters runningEWTX$EWTXTrimming-2% shares · 2 quarters runningAPGE$APGETrimming-44% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/perceptive-advisors-llc-1224962

PERCEPTIVE ADVISORS LLC 13F holdings — Q2 2026

$6.7B portfolio (+30.4% QoQ) · 109 holdings · Q2 2026 13F · top 10 are 49% of the stock portfolio

Includes $221.3M of put/call options ($197.2M puts, $24.1M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $6.4B. Weights use the stock portfolio.

All holdings — PERCEPTIVE ADVISORS LLC (Q2 2026)

109 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
EWTX$EWTXEdgewise Therapeutics, Inc.$177.7M-1%
APGE$APGEApogee Therapeutics, Inc.$173.6M-15%
AMLX$AMLXAmylyx Pharmaceuticals, Inc.$149.7M+0.6%
MGTX$MGTXMeiraGTx Holdings plc$145.7M+4%
ORKA$ORKAOruka Therapeutics, Inc.$128.0M-4%
INBX$INBXInhibrx Biosciences, Inc.$123.0M-10%
PTGX$PTGXProtagonist Therapeutics, Inc$120.4M-20%
SLDB$SLDBSolid Biosciences Inc.$118.9M—
ZYME$ZYMEZymeworks Inc.$109.3M+19%
TNGX$TNGXTango Therapeutics, Inc.$105.6M+318%
IMTX$IMTXImmatics N.V.$105.2M—
NRIX$NRIXNurix Therapeutics, Inc.$104.8M+16%
BCRX$BCRXBIOCRYST PHARMACEUTICALS INC$103.1M+39%
RVMD$RVMDRevolution Medicines, Inc.$98.8M+104%
AVLN$AVLNAvalyn Pharma Inc.$88.1MNew

What changed in Q2 2026

Against the previous quarter's 13F: 27 new, 30 added to, 28 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.

New positions (27)

  • KARD$KARDKardigan, Inc.$195.6M

    first bought this quarter

  • AVLN$AVLNAvalyn Pharma Inc.$88.1M

    first bought this quarter

  • BIIB$BIIBBIOGEN INC.$59.7M

    first bought this quarter

  • UNH$UNHUNITEDHEALTH GROUP INC$48.5M

    first bought this quarter

  • PUTSPDR SERIES TRUST - ST STR SP BIOT$47.5M

    first bought this quarter

  • CRL$CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.$31.8M

    first bought this quarter

+21 more in the Excel export

Added to (30)

  • RLAY$RLAYRelay Therapeutics, Inc.+45%

    now $263.9M · held 3 qtrs, 3 adds in a row

  • TNGX$TNGXTango Therapeutics, Inc.+318%

    now $105.6M · held 3 qtrs, 3 adds in a row

  • RVMD$RVMDRevolution Medicines, Inc.+104%

    now $98.8M · held 8+ qtrs, 2 adds in a row

  • SYRE$SYRESpyre Therapeutics, Inc.+14%

    now $383.5M · held 8+ qtrs, 3 adds in a row

  • CORT$CORTCORCEPT THERAPEUTICS INC+697%

    now $34.6M · held 2 qtrs, 2 adds in a row

  • BCRX$BCRXBIOCRYST PHARMACEUTICALS INC+39%

    now $103.1M · held 3 qtrs, 3 adds in a row

+24 more in the Excel export

Trimmed (28)

  • ASND$ASNDAscendis Pharma A/S-24%

    now $310.4M · held 5 qtrs

  • DYN$DYNDyne Therapeutics, Inc.-42%

    now $59.7M · held 8+ qtrs

  • GH$GHGuardant Health, Inc.-86%

    now $6.2M · held 3 qtrs

  • ABVX$ABVXAbivax S.A.-77%

    now $9.9M · held 4 qtrs, 2 trims in a row

  • APGE$APGEApogee Therapeutics, Inc.-15%

    now $173.6M · held 8+ qtrs, 2 trims in a row

  • PTGX$PTGXProtagonist Therapeutics, Inc-20%

    now $120.4M · held 8+ qtrs, 2 trims in a row

+22 more in the Excel export

Sold out (12)

  • CNTA$CNTACentessa Pharmaceuticals plcwas $208.9M

    held 9+ qtrs

  • DAWN$DAWNDay One Biopharmaceuticals, Inc.was $37.6M

    held 1 qtr

  • DRUG$DRUGBRIGHT MINDS BIOSCIENCES INC.was $27.5M

    held 6 qtrs

  • BLTE$BLTEBELITE BIO, INCwas $24.2M
  • EVMN$EVMNEvommune, Inc.was $10.3M
  • NMRA$NMRANeumora Therapeutics, Inc.was $10.0M

+6 more in the Excel export

Firm AUM (Form ADV): $11.8B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F PERCEPTIVE ADVISORS LLC has filed, 26 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow PERCEPTIVE ADVISORS?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of PERCEPTIVE ADVISORS's top 20 holdings: 33/100 (our AI quality score, weighted by position size; 9 of the 20 are scored)

Top 10 since filing

-17.9%

Value-weighted move of the 10 largest stock positions

Turnover

14%

Last quarter; 86% over the last 4

Top 10 weight

49%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

77%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

PERCEPTIVE ADVISORS LLC disclosed 109 positions worth $6.7B in its Form 13F-HR for Q2 2026 — $6.4B in common stock plus $221.3M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 10.6% of the equity portfolio, followed by $SYRE and $CELC. During the quarter the fund opened 27 new positions and exited 12 — including a new stake in $KARD and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (99.9% of disclosed assets). All figures are sourced directly from PERCEPTIVE ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1224962.

Funds like this

managers whose biggest positions overlap PERCEPTIVE ADVISORS's
Affinity Asset Advisors, LLC$2.21B 13F book · 13 shared top holdingsSYREROIVPRAXAPGEParadigm Biocapital Advisors LP$5.34B 13F book · 8 shared top holdingsSYRENUVLEWTXAPGEBAKER BROS. ADVISORS LP$19.96B 13F book · 11 shared top holdingsCELCRYTMPRAXRVMDDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 7 shared top holdingsPRAXNUVLCELCBCRXRA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 7 shared top holdingsRYTMEWTXNUVLORKARTW INVESTMENTS, LP$11.71B 13F book · 8 shared top holdingsSYRECELCORKAPTGX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: PERCEPTIVE ADVISORS LLC

13F Pro is an AI hedge fund tracker and stock research platform. For PERCEPTIVE ADVISORS LLC (SEC CIK: 1224962), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in PERCEPTIVE ADVISORS LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.